Alternatives to Chemotherapy: What to Compare First

One of the most common mistakes in cancer care is assuming chemotherapy is the next step before staging, biomarker testing, and local treatment options are fully reviewed.

Depending on the cancer type, stage, and tumor biology, treatments such as immunotherapy, targeted therapy, surgery, precision radiation, or hormone therapy may be reasonable options to replace, delay, or reduce the need for chemo.

This overview is educational and does not replace advice from your oncology team. Treatment decisions are usually individualized, and for some cancers, chemotherapy still plays an important role on its own or in combination with other therapies.

What “alternatives to chemotherapy” actually means

In cancer care, an alternative to chemotherapy usually means an established treatment that may be used instead of traditional chemo in certain situations. It does not mean an unproven or fringe approach.

These options often have a different safety profile rather than no side effects at all. For example, immunotherapy may avoid hair loss and severe nausea for some patients, while targeted therapy may spare more healthy cells but still require close lab and symptom monitoring.

The main question is not whether one option is simply “safer.” The better question is which treatment matches your cancer type, biomarker results, treatment goal, and tolerance for side effects.

Option	When it may be worth reviewing first
Immunotherapy	When PD-L1, MSI-H/dMMR, TMB, or cancer-specific guidelines suggest checkpoint inhibitors may work well
Targeted therapy	When genomic testing finds an actionable mutation such as EGFR, ALK, ROS1, BRAF, RET, NTRK, HER2, or a PARP-sensitive profile
Surgery or local ablation	When the cancer is early-stage, limited in one area, or a small lesion may be removed or destroyed directly
Precision radiation therapy	When the tumor is localized, surgery is not ideal, or a short, focused course such as SBRT may control the disease
Hormone therapy	When the cancer is hormone-sensitive, such as estrogen-receptor-positive breast cancer or many prostate cancers

5 established options that may reduce or replace chemotherapy

1) Immunotherapy

Checkpoint inhibitors help the immune system recognize and attack cancer by blocking pathways such as PD-1, PD-L1, or CTLA-4. A well-known example is pembrolizumab, and the FDA page for pembrolizumab (Keytruda) shows how its approved uses vary by cancer type and biomarker status.

For some patients, immunotherapy may offer a less chemo-like side-effect pattern and, in selected settings, longer-lasting responses. The National Cancer Institute’s immunotherapy overview explains how these treatments work across different cancers.

The main tradeoff is that side effects can be immune-related rather than dose-related. Problems such as thyroid inflammation, colitis, skin reactions, hepatitis, or pneumonitis may need prompt treatment, and the Cancer.Net guide to immunotherapy side effects is a useful patient reference.

Often reviewed when PD-L1 is high, MSI-H/dMMR is present, TMB is high, or guidelines support an immunotherapy-first approach.
May be given alone or combined with chemotherapy, radiation, or surgery depending on the setting.
Questions to ask: What are my PD-L1, MSI/MMR, and TMB results, and do they change whether chemo is needed?

2) Targeted therapy

Targeted therapy is used when testing finds a specific mutation or protein that helps drive the cancer. These drugs may target EGFR, ALK, ROS1, BRAF, RET, NTRK, HER2, or DNA-repair pathways, among others.

When the target is a strong match, targeted drugs can sometimes work better than standard chemotherapy in that biomarker-defined group. The NCI overview of targeted therapies explains why genomic testing is often central to this decision.

Many targeted therapies are oral medications, which can make treatment logistics easier for some patients. Side effects are usually drug-specific, such as rash, diarrhea, blood pressure changes, or liver test abnormalities, so regular monitoring still matters.

Often reviewed after comprehensive genomic profiling of the tumor, and in some cases blood-based molecular testing.
May delay or avoid chemotherapy when a clear driver mutation is found.
Questions to ask: Has my tumor had full genomic testing, and is there an actionable mutation with an approved targeted drug?

3) Surgery and local ablation

If the tumor is removable and still localized, surgery may offer the most direct path to treatment without whole-body chemotherapy. Small tumors in organs such as the liver, kidney, or lung may also be treated with ablation methods like radiofrequency, microwave, or cryoablation.

This option is usually most relevant in early-stage disease or limited metastatic disease where the cancer can be treated locally. The NCI surgery overview explains how surgery fits into both curative and symptom-relief plans.

The key issues to compare are margins, lymph node involvement, recovery time, and whether adjuvant treatment may still be recommended afterward. Even when surgery is successful, some cancers still need added therapy based on pathology results.

Often reviewed when scans suggest the disease is confined to one area.
May help patients avoid systemic therapy or limit it to a shorter course.
Questions to ask: Am I a candidate for surgery or ablation, and what would determine whether I still need treatment afterward?

4) Precision radiation therapy

Modern radiation is much more precise than older techniques. Options such as SBRT, IMRT, and, in selected cases, proton therapy can focus dose on the tumor while limiting exposure to nearby organs.

For some localized cancers, especially when surgery is not a good fit, radiation may control the disease without chemotherapy. The American Cancer Society’s radiation therapy overview gives a practical patient-friendly explanation, and the NCI proton beam therapy page helps explain where proton treatment may be considered.

The main comparison points are tumor location, number of treatments, nearby organs at risk, and whether the goal is cure or symptom relief. Side effects are usually limited to the treated area, but they can still be important depending on the dose and body site.

Often reviewed for early-stage tumors, symptom control, or select oligometastatic disease.
May be especially useful when a short treatment course is possible, such as SBRT in certain settings.
Questions to ask: Could focused radiation control my cancer, and would proton therapy offer a meaningful advantage in my case?

5) Hormone therapy

Some cancers rely on hormones to grow, and endocrine therapy works by blocking or lowering those signals. This is common in estrogen-receptor-positive breast cancer and in many prostate cancers.

Compared with chemotherapy, hormone therapy often has fewer short-term toxicities, though it may be taken for a long time. The American Cancer Society’s hormone therapy guide outlines common uses and side effects.

Important tradeoffs include bone health, hot flashes, joint pain, sexual side effects, and metabolic changes. In the right setting, hormone therapy may control disease for long periods or reduce recurrence risk without traditional chemo.

Often reviewed when pathology shows the cancer is hormone-sensitive.
May be the main systemic therapy in some early-stage and metastatic cases.
Questions to ask: Is my cancer hormone-driven, and would endocrine therapy replace chemo or be used alongside other treatments?

How Keytruda and similar drugs fit into treatment plans

Keytruda and other checkpoint inhibitors are not used the same way across all cancers. They may be used alone, with chemotherapy, before surgery, after surgery, or in tumor-agnostic settings such as MSI-H/dMMR disease, depending on the evidence for that cancer.

That is why biomarker testing matters so much before treatment starts. In some lung cancers with high PD-L1 expression, for example, immunotherapy alone may be reviewed, while in other cancers the benefit may be stronger when it is combined with chemo or radiation.

If you are trying to understand whether a non-chemo plan is realistic, ask whether immunotherapy would replace chemotherapy, delay it, or simply be added to it. Those are very different decisions in terms of side effects, clinic visits, and expected benefit.

Questions to ask before deciding

Has my diagnosis and stage been confirmed with the right pathology and imaging?
Have we done all relevant biomarker testing, including PD-L1, MSI/MMR, TMB, and genomic profiling where appropriate?
Is there a treatment that may replace chemotherapy, or are we really comparing chemo alone versus chemo plus another therapy?
Would surgery, ablation, or focused radiation treat the cancer locally instead of using systemic treatment first?
What side effects are most likely with this option, and what symptoms should I report right away?
How will we know if the treatment is working, and what is the backup plan if it does not?

When a clinical trial or second opinion may help

If your case sits in a gray area, a second opinion may clarify whether chemotherapy can reasonably be avoided or deferred. This can be especially useful when biomarker results are complex, the cancer is uncommon, or several treatment paths seem possible.

Clinical trials may also expand your options, particularly in targeted therapy and immunotherapy. The National Cancer Institute clinical trials page explains how trials are designed and how to start reviewing them with your care team.

Key points to remember

Alternatives to chemotherapy are often standard, evidence-based treatments rather than fringe options.
Immunotherapy, targeted therapy, surgery or ablation, precision radiation therapy, and hormone therapy may be worth reviewing depending on the cancer and biomarkers.
“Safer” usually means a different side-effect profile, not an absence of risk.
Biomarker testing, cancer stage, treatment goals, and overall health often drive whether a non-chemo plan makes sense.
A careful discussion with your oncology team is the best way to compare whether chemotherapy should be avoided, delayed, combined, or still used first.